<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04848233</url>
  </required_header>
  <id_info>
    <org_study_id>DG2101_CGM</org_study_id>
    <nct_id>NCT04848233</nct_id>
  </id_info>
  <brief_title>Using CGM for Evaluating Effects of Food on Glucose Regulation in Healthy Humans</brief_title>
  <official_title>Development of Methodology for Use of Continuous Blood Glucose Measurements When Evaluating Meal Effects on Glucose Regulation - a Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DoubleGood AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>starScience GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>DoubleGood AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The specific goal of this pilot study is to evaluate if it is possible to detect a&#xD;
      statistical difference in postprandial glycemia after meals served with and without a drink&#xD;
      previously shown to reduce postprandial glycemia by about 25%. A third drink, with a new&#xD;
      recipe, is also included for comparisons. Six participants will carry continuous blood&#xD;
      glucose monitors for 10 days and follow a specific meal schedule. The data from this study&#xD;
      will form the basis for forming hypothesis of future studies as well as make appropriate&#xD;
      calculations of statistical power.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Actual">May 26, 2021</completion_date>
  <primary_completion_date type="Actual">May 26, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postprandial glucose response</measure>
    <time_frame>From start of meal (0 min) to 120 min postprandially</time_frame>
    <description>Incremental area under the blood glucose curve after each meal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemic variability</measure>
    <time_frame>24 hour cycles</time_frame>
    <description>Variation in blood glucose levels</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Glycemic Control</condition>
  <condition>Diet, Food and Nutrition</condition>
  <arm_group>
    <arm_group_label>Drink intervention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo and two drinks containing a blend of five amino acids and chromium picolinate, are included with every main meal and served in a standardized, non-randomised order.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Drinks containing 5AA+CrPic and Placebo</intervention_name>
    <description>Same diet will be repeated for 3 days in a row and the beverage switched every day. 3 periods of 3 days are included in the study.</description>
    <arm_group_label>Drink intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI 25-29.9 kg/m^2&#xD;
&#xD;
          -  HOMA-IR &lt; 2.5&#xD;
&#xD;
          -  Fasting glucose &lt; 6.1 mmol/L&#xD;
&#xD;
          -  Stable weight since 3 months&#xD;
&#xD;
          -  Access to iPhone with Bluetooth 4.0 and iOS 13 or later&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Pharmacological treatment known to interfer with metabolism&#xD;
&#xD;
          -  Antibiotics treatment the latest 3 months&#xD;
&#xD;
          -  Vegetarian/Vegan diet&#xD;
&#xD;
          -  Use of tobacco&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elin Ostman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aventure AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aventure AB</name>
      <address>
        <city>Lund</city>
        <zip>223 63</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

